Explore 3 Stock Ideas & Industry Insights Download Free Report

Rezolute Inc

Company price
3.93 USD -0.27 ( 6.43%)
Last update at 2026-11-20T21:00:00Z
VOLUME
2272532
Market Cap
148.10M

Momentum Score

…

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.86
Low
4.23
High
52 Week Price Range
0.72
Low
3.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
4.20
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-48.79%
Net Debt
-13.56M
ROCE
-43.69%
Diluted EPS TTM
-1.18

Insight Announcement

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -51.79M -41.06M -20.90M -20.33M -30.45M
Net income -51.79M -38.78M -21.28M -20.33M -30.42M
Selling general administrative 12.18M 9.36M 7.91M 6.07M 6.82M
Reconciled depreciation 0.03M 0.01M 0.01M 0.02M 0.05M
Ebit -51.78M -41.84M -22.89M -20.52M -25.94M
Ebitda -51.75M -41.52M -22.30M -20.32M -25.47M
Depreciation and amortization 0.03M 0.32M 0.59M 0.21M 0.48M
Non operating income net other - 2.59M - - -
Operating income -55.99M -41.84M -22.89M -20.52M -25.94M
Other operating expenses 55.99M 41.61M 22.38M 20.52M 25.90M
Interest expense 0.00M 1.81M 0.38M 0.00M 4.96M
Interest income 4.21M 0.08M 0.06M 0.19M 0.06M
Net interest income 4.21M -1.73M -0.31M 0.19M -4.90M
Income tax expense - -2.28M 0.38M -0.19M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 55.99M 41.61M 22.38M 20.52M 25.90M
Total other income expense net -0.01M 0.78M 1.99M 0.19M -4.50M
Net income from continuing ops -51.79M -41.06M -20.90M -20.33M -30.45M
Net income applicable to common shares -51.79M -41.06M -20.90M -20.33M -32.72M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 123.72M 152.42M 42.61M 10.96M 12.25M
Intangible assets - - - - 0.03M
Other current assets - 1.69M 0.95M 0.56M 0.57M
Total liab 7.55M 2.95M 16.51M 3.60M 10.50M
Total stockholder equity 116.17M 149.47M 26.10M 7.37M 1.75M
Deferred long term liab - - 0.19M 0.03M -
Other current liab 1.39M 1.22M 0.67M 2.09M 7.32M
Common stock 0.04M 0.03M 0.01M 0.01M 0.21M
Capital stock 0.04M 0.03M 0.01M 0.01M 0.21M
Retained earnings -260.99M -209.20M -168.14M -147.24M -126.90M
Other liab 0.41M 0.41M 0.39M 0.21M 2.12M
Other assets 0.15M 0.15M 0.19M 0.03M 0.04M
Cash 16.04M 150.41M 41.05M 9.96M 11.57M
Total current liabilities 5.20M 2.46M 1.97M 3.23M 8.38M
Net debt -13.56M -150.22M -26.63M -9.54M -11.56M
Short term debt 0.54M 0.11M 0.27M 0.24M 0.01M
Short long term debt - - - - 0.01M
Short long term debt total 2.48M 0.19M 14.42M 0.41M 0.01M
Other stockholder equity 377.47M 358.63M 194.23M 154.59M 128.44M
Property plant equipment 2.19M 0.02M 0.42M 0.42M 0.04M
Total current assets 104.91M 152.10M 41.99M 10.52M 12.14M
Long term investments 16.47M - - - -
Net tangible assets 116.17M 149.47M 26.10M 7.37M 1.72M
Short term investments 85.86M - - - -
Long term debt - 0.41M 13.97M - -
Accounts payable 3.27M 1.13M 1.03M 0.89M 1.05M
Accumulated other comprehensive income -0.35M - - -14.00M -0.00M
Common stock total equity - 0.03M 0.01M 0.01M 0.06M
Retained earnings total equity - -209.20M - - -
Non currrent assets other 0.15M 0.15M 0.19M 0.03M 0.04M
Non current assets total 18.81M 0.32M 0.62M 0.45M 0.11M
Capital lease obligations 2.48M 0.19M 0.45M 0.41M -
Long term debt total - 0.41M - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -101.46M -101.31M -101.31M -101.31M 0.23M
Change to liabilities 2.14M 0.22M 0.14M 0.33M -0.93M
Total cashflows from investing activities -101.46M -101.46M -101.46M -101.46M 0.23M
Net borrowings - -16.27M 15.00M 15.00M 15.00M
Total cash from financing activities 11.57M 148.98M 51.53M 22.55M 25.00M
Change to operating activities -1.11M -0.63M -2.26M -7.82M 9.29M
Net income -51.79M -41.06M -20.90M -20.33M -30.45M
Change in cash -134.37M 109.36M 31.09M -1.62M 9.93M
Begin period cash flow 150.41M 41.05M 9.96M 11.57M 1.65M
End period cash flow 16.04M 150.41M 41.05M 9.96M 11.57M
Total cash from operating activities -44.48M -39.62M -20.44M -24.17M -15.30M
Issuance of capital stock 12.33M 122.82M 41.00M 24.05M 25.00M
Depreciation 0.03M 0.01M 0.01M 0.02M 0.05M
Sale purchase of stock - 179.76M - - -
Other cashflows from financing activities -0.76M 52.95M 10.53M -1.50M 0.23M
Change to netincome 6.25M -2.86M 2.48M 3.64M 2.45M
Capital expenditures 0.15M 0.15M 0.15M 0.15M 0.05M
Cash flows other operating - 1.58M - - -
Cash and cash equivalents changes - 109.36M - - -
Change in working capital 1.02M -0.64M -2.12M -7.49M 8.36M
Stock based compensation 7.27M 3.69M 3.96M 3.32M 2.64M
Other non cash items 0.35M -1.61M 0.38M 0.22M 4.12M
Free cash flow -44.63M -39.62M -20.44M -24.17M -15.35M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RZLT
Rezolute Inc
-0.27
6.43%
3.93 - - - 1.17 -0.29
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Rezolute Inc

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

201 Redwood Shores Parkway, Redwood City, CA, United States, 94065

650 206 4507

57

Name Title Year Born
Mr. Nevan Charles Elam J.D. Founder, CEO & Director 1967
Dr. Brian Kenneth Roberts M.D. Chief Medical Officer 1975
Mr. Chris Milks VP & Head of Fin. NA
Mr. Michael R. Deperro Sr. VP & Head of Technical Operations NA
Dr. Davelyn Eaves Hood M.B.A., M.D. Director and Head of Scientific & Patient Affairs NA
Mr. Michael Covarrubias VP & Head of CMC NA
Dr. Raj Agrawal M.D. VP & Head of Ophthalmological Clinical Devel. NA
Ms. Robyn Sweinhart VP & Head of Quality NA
Ms. Erin O'Boyle VP & Head of Clinical Operations NA
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…